Concepts represent early planning stages for program announcements, requests for applications, notices of special interest, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.
Note: Council approval does not guarantee that a concept will become an initiative.
Table of Contents
Fiscal Year (FY) 2024 Division of AIDS (DAIDS) Concepts
- Competing Revisions of Existing NIH Centers for AIDS Research (CFAR) and Developmental Centers for AIDS Research (DCFAR) Grants
- Notice of Special Interest (NOSI)—Ending the HIV Epidemic (EHE)
FY 2025 DAIDS Concepts
- Strategies for Eliminating HIV Proteins
- Limited Interaction Targeted Epidemiology—Epidemiology of Transmission and Treatment of HIV Among Vulnerable Populations in Latin America (LITE-LA)
- Gender-Affirming Hormone Therapy, Resilience, Immunology, Pharmacokinetics (GRIP)
- Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II)
- Engineering Durable HIV Vaccine Responses (ENDURE)
- Strategies for Controlled Release of HIV Vaccines (SCORE-H)
Competing Revisions of Existing NIH Centers for AIDS Research (CFAR) and Developmental Centers for AIDS Research (DCFAR) Grants
For the published program announcement with special receipt, referral, and/or review considerations, check the December 21, 2023 Guide announcement, Limited Competition—Revision Applications of Existing NIH Centers for AIDS Research (CFAR) and Developmental Centers for AIDS Research (D-CFAR) Grants (P30, Clinical Trial Not Allowed).
Notice of Special Interest (NOSI)—Ending the HIV Epidemic (EHE)
For the published notice of special interest, check the August 6, 2024 Guide notice, Notice of Special Interest (NOSI): Ending the HIV Epidemic (EHE).
Strategies for Eliminating HIV Proteins
For the published requests for applications, check the August 29, 2024 Guide announcements.
- Strategies for Eliminating HIV Proteins (R21, Clinical Trial Not Allowed)
- Strategies for Eliminating HIV Proteins (R01, Clinical Trial Not Allowed)
Limited Interaction Targeted Epidemiology: Epidemiology of Transmission and Treatment of HIV Among Vulnerable Populations in Latin America (LITE-LA)
For the published request for applications, check the March 28, 2024 Guide announcement, Limited Interaction Targeted Epidemiology: Epidemiology of Transmission and Treatment of HIV Among People Who Are at Increased Risk for HIV Infection in Latin America (LITE-LA), (UG3/UH3).
Gender-Affirming Hormone Therapy, Resilience, Immunology, Pharmacokinetics (GRIP)
For the published request for applications, check the March 28, 2024 Guide announcement, Interaction Between ARVs and Hormones in HIV and Co-infections (R01 Clinical Trial Optional).
Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II)
For the published request for applications, check the October 25, 2023 Guide announcement, Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33, Clinical Trial Not Allowed).
Engineering Durable HIV Vaccine Responses (ENDURE)
For the published request for applications, check the April 25, 2024 Guide announcement, Engineering Durable HIV Vaccine Responses (ENDURE) (R01, Clinical Trial Not Allowed).
Strategies for Controlled Release of HIV Vaccines (SCORE-H)
For the published request for applications, check the March 27, 2024 Guide announcement, Strategies for Controlled Release of HIV Vaccines (SCORE-H) (R01 Clinical Trial Not Allowed).